Merus's Petosemtamab Shows 40.4% Response Rate in Head & Neck Cancer Trial

Merus's Petosemtamab Shows 40.4% Response Rate in Head & Neck Cancer Trial

Submitted by admin on December 2, 2024 - 10:57am
Source: 
Stock Titan
News Tags: 
Merus
petosemtamab
squamous cell carcinoma of the head and neck
head and neck cancer
Headline: 
Merus's Petosemtamab Shows 40.4% Response Rate in Head & Neck Cancer Trial
snippet: 

Merus (MRUS) announced updated clinical data for petosemtamab in treating recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). 

Do Not Allow Advertisers to Use My Personal information